T cell activating bispecific antigen binding molecules
AssigneeHoffmann-La Roche Inc.
InventorsChristian Klein, Ekkehard Moessner, Ralf Hosse, Peter Bruenker, Pablo Umana, Christiane Neumann
Life of this patent
Estimating the term…
Abstract
The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells comprising a common light chain. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
Claims14
A T cell activating bispecific antigen binding molecule comprising a first antigen binding moiety that binds to CD3 and a second antigen binding moiety that binds to Folate Receptor 1 (FolR1),
- wherein the second antigen binding moiety comprises the heavy chain variable domain (VH) sequence of antibody 9D11 encoded by the sequence of SEQ ID NO:
- 171 and the light chain variable domain (VL) sequence of antibody 9D11 encoded by the sequence of SEQ ID NO:
- 172.
Dependencies are inferred from the claim text.